title: Treatment of the cutaneous pain of acute herpes zoster with 9% lidocaine (base) in petrolatum/paraffin ointment.
abstract: BACKGROUND
  Treatment of the pain of acute herpes zoster by local anesthetic injections has drawbacks. Topical percutaneous local anesthesia (TPLA) may offer another strategy of providing regional analgesia in affected patients.
  
  
  OBJECTIVE
  We evaluate the analgesic efficacy and safety of 9% (wt/vol) lidocaine (base) in petrolatum/paraffin ointment in patients with acute herpes zoster.
  
  
  METHODS
  Ointment was applied to the affected skin of 22 patients. Pain, tenderness, sensitivity to pinprick and cold, and blood lidocaine concentration were measured repeatedly during a 20-hour interval and intermittently thereafter.
  
  
  RESULTS
  Mean pain, tenderness, and cutaneous sensation scores were reduced at measurements taken from 4 to 20 hours after ointment application (p < 0.05), but not every patient obtained relief. No patient had local skin irritation or systemic toxic effects related to the local anesthetic.
  
  
  CONCLUSIONS
  TPLA is a promising therapy for control of cutaneous pain of acute herpes zoster. Controlled studies should be performed to prove efficacy, determine optimal TPLA formulation, and define dosage limits.
authors.affiliation: Department of Anesthesiology, Louisiana State University Medical Center, New Orleans.
authors.forename: J
authors.initials: J
authors.lastname: Riopelle
authors.forename: A
authors.initials: A
authors.lastname: Lopez-Anaya
authors.forename: R C
authors.initials: RC
authors.lastname: Cork
authors.forename: D
authors.initials: D
authors.lastname: Heitler
authors.forename: J
authors.initials: J
authors.lastname: Eyrich
authors.forename: A
authors.initials: A
authors.lastname: Dunston
authors.forename: A J
authors.initials: AJ
authors.lastname: Riopelle
authors.forename: W
authors.initials: W
authors.lastname: Johnson
authors.forename: A
authors.initials: A
authors.lastname: Ragan
authors.forename: M
authors.initials: M
authors.lastname: Naraghi
mesh_terms: D000208:Acute Disease; D000279:Administration, Cutaneous; D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006562:Herpes Zoster / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D009437:Neuralgia / Q000188:drug therapy / Q000382:microbiology; D009779:Occlusive Dressings; D009824:Ointments; D010146:Pain; D017288:Pain Threshold / Q000187:drug effects; D010232:Paraffin; D010577:Petrolatum; D012449:Safety; D012677:Sensation / Q000187:drug effects; D017193:Skin Diseases, Viral / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D009824:Ointments; D010232:Paraffin; D010577:Petrolatum; D008012:Lidocaine